Acne Vulgaris Clinical Trial
Official title:
Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne Cream in West Jakarta
This study was conducted to see whether there was a decrease in the degree of acne vulgaris / pimple, to find out what proportion of respondents experienced a decrease in severity and who did not experience a decrease in the severity of acne vulgaris after the use of an anti-acne cream combination containing active ingredients such as; Tretinoin 0.05% (derivatives of Vitamin A), Clindamycin 5% (antibiotics), and Dexamethasone 0.05% (anti-inflammatory) for 1 month of use.
This research was conducted based on the results of epidemiological studies that the group of
adolescents aged 14-19 years had a fairly high prevalence of acne vulgaris, which amounted to
83-85% for female, 95-100% for male and this prevalence rate was increasing over the years.
Acne vulgaris is not a dangerous disease, but has a large enough impact for sufferers,
especially teenagers. Physical and psychological effects can cause anxiety, depression, and
reduce the confidence of sufferers.
Many drugs for acne vulgaris are sold freely and can be bought by everyone without the need
to consult a doctor first, coupled with the lack of knowledge of adolescent groups about acne
vulgaris and its treatment options, this causes the lack of accurate acne treatment and
increases the risk of effects side of the drug. The use of topical medicines in the form of a
combination of anti-acne cream is one of the best choices because all the components needed
to deal with acne can be combined to become one so that it is more effective and efficient
The short-term goal of this research is to find out what proportion of respondents with mild,
moderate and severe acne before being given an intervention in the form of using a
combination of anti-acne cream, the proportion of respondents with mild, moderate and severe
acne after being given an intervention, the proportion of respondents who were given
intervention and experienced decrease the severity of acne vulgaris, and find out the
relationship between the use of a combination of anti-acne cream with a decrease in the
severity of acne vulgaris.
This research is an experimental design clinical trial research. The research hypothesis is
that the use of a combination of anti-acne creams can reduce the severity of acne vulgaris.
The study population and sample were in the form of a group of adolescents aged 14-19 years,
located in the sampling area, and met the inclusion criteria. The number of samples is 186
respondents .
The ingredients contained in the combination of anti-acne creams are commonly used
ingredients and are one of the first-line treatments for acne vulgaris, namely Tretinoin
0.05% (Vitamin A derivatives), Clindamycin 3% (antibiotics), and Dexamethasone 0.05%
(anti-inflammation). Based on the literature it is known that these three active substances
have proven to be effective in treating acne vulgaris. Side effects can occur mild and not
like irritation, skin peeling, redness, and local allergic reactions. These side effects can
be minimized by using according to doctor's instructions and will disappear if the use of the
cream is stopped.
We researchers always uphold the investigator's ethics and professionalism while conducting
this research, and do not fight the medical oath we have taken.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |